Sanofi secures two breakthrough nods in China for rare blood disorders
Qfitlia is the first antithrombin (AT)-lowering therapy approved for routine prophylaxis in hemophilia
Qfitlia is the first antithrombin (AT)-lowering therapy approved for routine prophylaxis in hemophilia
The new powder formulation gives children and adults living with Rett syndrome greater flexibility and choice in dose volume and taste
Clinical trial enrollment has long been a bottleneck in drug development
The plant can reach an annual capacity of 300 crore tablets and 90 crore capsules
More than five drug candidates from his team progressed to human trials including drugs like Rilematovir (Phase IIb), and Bedaquiline
In her previous roles, Menon led significant digital transformation efforts, implementing predictive analytics, automation
Her journey includes leading HR for large and diverse teams across sales, marketing, corporate functions, and R&D
All pending litigation between Biocon Biologics, Regeneron, and Bayer will be dismissed
Subscribe To Our Newsletter & Stay Updated